Vertex and CRISPR Therapeutics Announce US FDA Approval of ...

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease · leads ...

FDA Approves First Gene Therapies to Treat Patients with Sickle ...

The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years ...

CRISPR Therapeutics and Vertex Announce FDA…

04, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug ...

Vertex and CRISPR Therapeutics Announce Authorization of the ...

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom ...

CRISPR Therapeutics Announces Completion of FDA…

CRISPR Therapeutics announces completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease.

Press Release - CRISPR Therapeutics

“We are pleased with the approval of CASGEVY in TDT well ahead of the PDUFA date,” said Samarth Kulkarni , Ph.D., Chairman and Chief Executive ...

Vertex, CRISPR Therapeutics Get FDA Approval for ... - Investopedia

Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced Friday that the Food and Drug Administration (FDA) gave them approval for use of the ...

FDA approves Vertex, CRISPR's Casgevy for beta-thalassemia

Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing ... U.S. regulator signed off on Casgevy ...

Vertex and CRISPR Therapeutics Announce US FDA Approval of ...

BOSTON & ZUG, Switzerland, December 08, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) ...

FDA Approves Vertex, CRISPR's Casgevy to Treat Beta Thalassemia

Vertex Pharmaceuticals and CRISPR Therapeutics have secured another FDA approval ... CRISPR gene editing therapy to reach the U.S. market. The ...

CRISPR Therapeutics and Vertex Announce FDA Has…

In addition to the acceptance of the IND announced today, CRISPR and Vertex previously announced that they had obtained approvals of Clinical Trial Applications ...

CRISPR Therapeutics and Vertex Pharmaceuticals…

CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of ...

FDA Accepts Biologics License Applications for…

CRISPR Therapeutics (Nasdaq: CRSP) today announced that the · U.S. Food and Drug Administration · European Hematology Association Congress ...

CRISPR Therapeutics and Vertex Announce FDA Fast Track ...

CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...

CRISPR Therapeutics and Vertex Announce FDA Fast Track ...

The companies announced in February 2019 that the first patient had been enrolled in a Phase 1/2 clinical study of CTX001 in severe SCD in the U.S. and is ...

Press Release - CRISPR Therapeutics

The IND was submitted to the FDA in April to support the planned initiation of a Phase 1/2 trial in the U.S. in adult patients with sickle cell disease. CRISPR ...

CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA

CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from ...

US FDA approves Vertex/CRISPR gene therapy for an inherited ...

The U.S. health regulator approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a blood disorder requiring regular ...

FDA signs off on Vertex, CRISPR's gene therapy for sickle cell

Vertex and CRISPR have won FDA approval for sickle cell disease therapy Casgevy. The transformational treatment is a potential cure for the ...

US FDA approves Vertex/CRISPR gene therapy for an inherited ...

The U.S. health regulator has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a rare blood disorder requiring ...